JP2015208312A - Variant glucose-6-phosphate dehydrogenase - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide heat-resistant glucose-6-phosphate dehydrogenase (G6 PDH) in which affinity to coenzyme NAD is improved.SOLUTION: A production method of the polypeptide comprises a polypeptide which has G6 PDH activity, and in which an amino acid residue at a specific position is substituted by other amino acid residue, and in which affinity to coenzyme NAD is improved as compared with the original G6 PDH; DNA encoding the polypeptide; a recombinant vector containing the DNA; a transformant containing the nine vectors; and steps of culturing transformant, in an amino acid sequence of heat-resistant G6 PDH derived from Geobacillus stearothermophilus.

Description

  The present invention relates to a mutant glucose-6-phosphate dehydrogenase with improved affinity for a coenzyme, a gene encoding the mutant enzyme, a recombinant vector containing the gene, and a transformant obtained from the vector And a method for producing a mutant G6PDH using the transformant.

  A clinical test drug using an enzyme that reacts specifically with a specific substrate is used for measuring various body molecules. For example, glucose-6-phosphate dehydrogenase (EC 1.1.1.49, hereinafter sometimes referred to as “G6PDH”) is expressed as nicotinamide adenine dinucleotide (hereinafter, “NAD”) as a coenzyme. Or an enzyme that catalyzes the substrate D-glucose-6-phosphate to D-glucono-1,5-lactone-6-phosphate, which requires nicotinamide adenine dinucleotide phosphate It is known that Document 1 can be used for quantification of creatine kinase, which is a myocardial infarction marker (Non-patent Document 1), and glucose, which is a diabetes marker (Non-Patent Document 2).

On the other hand, an enzyme fuel cell technology has been developed that mimics the catalytic reaction in the living body and generates electricity from a specific substrate such as glucose, which is an industry that requires higher levels of catalytic activity and stability than conventional applications. Enzymes are also being used in applications. For example, Non-Patent Document 3 introduces that G6PDH or the like is fixed to the cathode of a battery, and that glucose can be used as a fuel and an output of 0.322 mWcm ⁻² can be obtained.

  In the applications exemplified above, conventionally, as G6PDH, an enzyme collected from a microorganism such as Leuconostoc genus bacteria or yeast has been mainly used. For example, Non-Patent Document 4 discloses the G6PDH gene sequence of Leuconostoc mesenteroides, a Leuconostoc bacterium, and the amino acid sequence encoded by the gene. Patent Document 1 discloses a production method using Leuconostoc mesenteroid G6PDH gene sequence and recombinant E. coli. Patent Document 2 discloses a production method using Leuconostoc dextranix G6PDH gene sequence and recombinant E. coli.

  However, the conventional G6PDH has insufficient stability, and its improvement has been desired for practical use as a diagnostic agent. Thus, various searches for G6PDH with improved stability have been made so far. For example, G6PDH derived from Bacillus (reclassified to genus Geobacillus) and stearothermophilus (Patent Document 3), G6PDH derived from Lactobacillus (Patent Document 4), G6PDH derived from Pediococcus (Patent Document 5) And 6), and G6PDH derived from Aquifex Aeolicus (Non-patent Document 5) have been reported to have excellent heat resistance and thermal stability.

  Furthermore, improvement of stability by introducing a mutation into wild-type G6PDH has also been studied. For example, Patent Document 7 reports that the stability during storage in a solution state can be improved by introducing a specific amino acid substitution in the amino acid sequence of G6PDH derived from Leuconostoc mesenteroides.

Japanese Patent Publication No. 5-503221 Japanese Patent Publication No. 5-87234 Japanese Patent Publication No. 63-43079 Japanese Patent Publication No. 3-995 JP-A-9-313174 JP-A-10-225293 JP 2001-37480 A

Clinical Chemistry Vol.19, No.2, p185-208, 1990, published by the Japanese Society for Clinical Chemistry Richard J., et al. L. Bonder and Donna C.I. Mead. Evaluation of Glucose-6-Phosphate Dehydrogenase from Leuconostoc mesenteroides in the Hexkinase Method for Determinating Glucose in Serum. CLIN. CHEM. , Vol. 20, no. 5, 1974, p. 586-90. Zhu Z et al. , Deep oxidation of glucose in enzymatic fuel cells through a synthetic enzymatic pathway con- taining a cascade of two colors. Biosens Bioelectron. Vol. 36, no. 1, 1012, p.110-5. W. Theodore Lee et al. , Cloning of the Gene and Amino Acid Sequence for Glucose 6-Phosphate Dehydrogenase from Leuconostoc mesenteroides. THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 266, No. 20, 1991, p. 13028-34. Ramesh B. Iyer et. al. , Cloning, expression, and characterization of the gsdA gene encoding thermophilic glucose-6-phosphate dehydrogenase from Aquifex aeolicus. Extremophiles, Vol. 6, 2002, p. 283-89.

  As described above, G6PDH has been conventionally used under relatively mild conditions in diagnostic drug applications, but as described in Non-Patent Document 3, it can also be used for industrial applications such as enzyme fuel cells. Has been sought. In such industrial applications, high heat resistance is required.

  Patent Document 7 introduces solution stabilization by site-specific amino acid substitution of Leuconostoc mesenteroides-derived G6PDH, but its heat resistance is said to be suitable for industrial applications as described above. hard.

  In addition, G6PDH disclosed in Non-Patent Document 5 has remarkable performance in terms of stability, but has a catalytic activity per unit weight of protein (hereinafter also referred to as specific activity) near room temperature of several U / Since it is extremely low at mg and hardly functions as a catalyst, it cannot be put to practical use.

  Furthermore, G6PDH disclosed in Patent Document 3 has heat resistance that can withstand heat treatment at 60 ° C. and has a relatively high specific activity at 30 ° C. of about 200 U / mg. However, it has a disadvantage that the affinity for coenzyme NAD is low (the Km value for NAD, which is an index of affinity is high). When the affinity for the coenzyme NAD is low, it is necessary to use more expensive NAD in the reaction system, leading to an increase in cost.

  Accordingly, an object of the present invention is to provide a thermostable G6PDH with improved affinity for the coenzyme NAD. More specifically, the present invention relates to a mutant G6PDH whose affinity for coenzyme NAD is improved by introducing a mutation into heat-resistant G6PDH derived from Geobacillus stearothermophilus, and coding for the mutant G6PDH It is an object of the present invention to provide a gene to be transformed, a recombinant vector containing the gene, a transformant obtained from the vector, and a method for producing a mutant G6PDH using the transformant.

  As a result of intensive studies to solve the above problems, the present inventors have determined that the 46th amino acid residue in the amino acid sequence (SEQ ID NO: 4) of heat-resistant G6PDH derived from Geobacillus stearothermophilus is another amino acid. It has been found that the affinity for the coenzyme NAD can be significantly improved by substitution with a residue. The present invention has been completed by further studies based on such knowledge.

That is, this invention provides the invention of the aspect hung up below.
Item 1. The polypeptide shown in any of the following (A) to (C):
(A) The 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is any one selected from the group consisting of threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine A polypeptide comprising an amino acid sequence substituted with an amino acid,
(B) The 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is any one selected from the group consisting of threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine In the amino acid sequence substituted with an amino acid, one or several amino acids other than the 46th amino acid are substituted, added, inserted or deleted, and have glucose-6-phosphate dehydrogenase activity, A polypeptide having an improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in No. 4;
(C) The 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is any one selected from the group consisting of threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine In the amino acid sequence substituted with an amino acid, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, and has glucose-6-phosphate dehydrogenase activity, A polypeptide having an improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase comprising the amino acid sequence shown in SEQ ID NO: 4.
Item 2. The polypeptide shown in any of the following (A) to (C):
(A) a polypeptide comprising an amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with threonine;
(B) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with threonine, one or several amino acids other than the 46th amino acid are substituted, added, inserted or deleted, and Polypeptide having glucose-6-phosphate dehydrogenase activity and improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 ,
(C) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with threonine, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, In addition, poly having a glucose-6-phosphate dehydrogenase activity and an improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase having the amino acid sequence shown in SEQ ID NO: 4 peptide.
Item 3. The polypeptide shown in any of the following (A) to (C):
(A) a polypeptide comprising an amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with cysteine,
(B) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with cysteine, one or several amino acids other than the 46th amino acid are substituted, added, inserted or deleted, and Polypeptide having glucose-6-phosphate dehydrogenase activity and improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 ,
(C) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with cysteine, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, In addition, poly having a glucose-6-phosphate dehydrogenase activity and an improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase having the amino acid sequence shown in SEQ ID NO: 4 peptide.
Item 4. The polypeptide shown in any of the following (A) to (C):
(A) a polypeptide comprising an amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with asparagine;
(B) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with asparagine, one or several amino acids other than the 46th amino acid are substituted, added, inserted or deleted, and Polypeptide having glucose-6-phosphate dehydrogenase activity and improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 ,
(C) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with asparagine, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, In addition, poly having a glucose-6-phosphate dehydrogenase activity and an improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase having the amino acid sequence shown in SEQ ID NO: 4 peptide.
Item 5. Item 5. A DNA encoding the polypeptide according to any one of Items 1 to 4.
Item 6. Item 6. The DNA according to Item 5, which is the DNA shown in (i) or (ii) below.
(I) SEQ ID NO: 76, 80, 64, 52, 56, 62, 66, 68, 70, 72, or 8
DNA comprising the base sequence shown in 4,
(Ii) Glucose-6-phosphate dehydrogenase activity and improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 DNA encoding a polypeptide and comprising a base sequence complementary to DNA consisting of the base sequence shown in SEQ ID NOs: 76, 80, 64, 52, 56, 62, 66, 68, 70, 72, or 84; DNA that hybridizes under stringent conditions.
Item 7. Item 7. A recombinant vector comprising the DNA according to item 5 or 6.
Item 8. Item 8. A transformant obtained by transforming a host with the recombinant vector according to Item 7.
Item 9. Item 9. The transformant according to Item 8, wherein the host is Escherichia coli.
Item 10. Item 10. The method for producing a polypeptide according to any one of Items 1 to 4, comprising a step of culturing the transformant according to Item 8 or 9.

  The polypeptide of the present invention has G6PDH activity, is excellent in heat resistance, and has a high affinity for coenzyme NAD, so that it can be used in a wide range of fields such as diagnostic agents and fuel cells. In particular, the polypeptide of the present invention has a high affinity for the coenzyme NAD and can reduce the amount of expensive NAD used in the reaction system, so that the enzymatic reaction can be carried out at a lower cost than conventional G6PDH. .

  Hereinafter, the present invention will be described in detail. In addition to the sequence listing, the 20 types of amino acid residues in the amino acid sequence are expressed by single letter abbreviations. That is, glycine (Gly) is G, alanine (Ala) is A, valine (Val) is V, leucine (Leu) is L, isoleucine (Ile) is I, phenylalanine (Phe) is F, tyrosine (Tyr) is Y , Tryptophan (Trp) is W, serine (Ser) is S, threonine (Thr) is T, cysteine (Cys) is C, methionine (Met) is M, aspartic acid (Asp) is D, glutamic acid (Glu) is E Asparagine (Asn) is N, glutamine (Gln) is Q, lysine (Lys) is K, arginine (Arg) is R, histidine (His) is H, and proline (Pro) is P.

  In this specification, expressions such as “R46F” are notation for amino acid substitution. For example, “R46F” means that the 46th amino acid R from the N-terminal side in a specific amino acid sequence is substituted with the amino acid F.

  In the present specification, the “nonpolar amino acid” includes alanine, valine, leucine, isoleucine, proline, methionine, phenylalanine, and tryptophan. In addition, “uncharged amino acid” includes glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The “acidic amino acid” includes aspartic acid and glutamic acid. The “basic amino acid” includes lysine, arginine, and histidine.

  In the present specification, glucose-6-phosphate dehydrogenase is sometimes referred to as “G6PDH”, and glucose-6-phosphate dehydrogenase activity is sometimes referred to as “G6PDH activity”.

  In the present specification, glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 is sometimes referred to as “wild type G6PDH”.

  In this specification, the activity 1U of G6PDH refers to the presence of 40 mM magnesium chloride, 2.6 mM glucose-6-phosphate water and 4 mM NAD in 84 mM Tris-HCl buffer (pH 9.0). Refers to the amount of enzyme capable of producing 1 micromolar NADH per minute.

1. Polypeptide The polypeptide of the present invention is a variant of the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 4, has G6PDH activity, and has a higher affinity for coenzyme NAD than wild-type G6PDH. It is a peptide.

  G6PDH is a glucose-6-phosphate dehydrogenase that uses nicotinamide adenine dinucleotide (hereinafter also referred to as NAD) or nicotinamide adenine dinucleotide phosphate as a coenzyme. G6PDH is an enzyme that catalyzes the dehydrogenation reaction of D-glucose-6-phosphate in combination with the reaction of adding hydrogen to the coenzyme, and is an enzyme classified as EC 1.1.49.

  One embodiment of the polypeptide of the present invention includes (A) a polypeptide comprising an amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with another amino acid.

  The “other amino acid” in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted is not particularly limited as long as the affinity for coenzyme NAD can be improved as compared with wild type G6PDH. Include threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine. Among these, from the viewpoint of further improving the affinity for the coenzyme NAD, preferably threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, and isoleucine; more preferably threonine, cysteine , Asparagine, glutamic acid, aspartic acid, serine, glutamine, and lysine; more preferably threonine, cysteine, asparagine, glutamic acid, aspartic acid, and serine; particularly preferably threonine, cysteine, and asparagine; most preferably threonine.

  Specific examples of the amino acid sequence of the polypeptide (A) are shown in SEQ ID NOs: 53, 57, 63, 65, 67, 69, 71, 73, 77, 81 and 85. The amino acid sequence shown in SEQ ID NO: 53 is an amino acid sequence in which amino acid substitution R46I is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 57 is an amino acid sequence in which amino acid substitution R46V is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 63 is an amino acid sequence in which amino acid substitution R46Q is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 65 is an amino acid sequence in which amino acid substitution R46N is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 67 is an amino acid sequence into which amino acid substitution R46K has been introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 69 is an amino acid sequence into which amino acid substitution R46D has been introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 71 is an amino acid sequence in which amino acid substitution R46E is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 73 is an amino acid sequence in which amino acid substitution R46S is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 77 is an amino acid sequence in which amino acid substitution R46T is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 81 is an amino acid sequence in which amino acid substitution R46C is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4). The amino acid sequence shown in SEQ ID NO: 85 is an amino acid sequence in which amino acid substitution R46G is introduced in the amino acid sequence of wild type G6PDH (SEQ ID NO: 4).

Moreover, the polypeptide shown to the following (B) and (C) is mentioned as another aspect of the polypeptide of this invention.
(B) Any one selected from the group consisting of threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine in the amino acid sequence shown in SEQ ID NO: 4 One or several amino acids other than the 46th amino acid sequence is substituted, added, inserted or deleted, and has glucose-6-phosphate dehydrogenase activity, A polypeptide having an improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase comprising the amino acid sequence shown in SEQ ID NO: 4.
(C) The 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is any one selected from the group consisting of threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine In the amino acid sequence substituted with the amino acid, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, and has glucose-6-phosphate dehydrogenase activity A polypeptide having improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4.

  Hereinafter, in the polypeptides (B) and (C), the amino acid site other than the 46th position in the amino acid sequence shown in SEQ ID NO: 4 may be referred to as “arbitrary modification site”.

  In the polypeptides (B) and (C) above, the aspect and preferred specific examples of the 46th amino acid substitution introduced in the amino acid sequence shown in SEQ ID NO: 4 are the same as in the case of the polypeptide (A). is there.

  The amino acid modification introduced into the arbitrary modification site of the polypeptide (B) may include only one type of modification (for example, substitution) from substitution, addition, insertion, and deletion, Two or more types of modifications (for example, substitution and insertion) may be included. In the polypeptide (B), the number of amino acids to be substituted, added, inserted or deleted at an arbitrary modification site may be one, plural or several, for example 1 to 10, preferably 1 to 5 More preferably 1 to 6, more preferably 1 to 3, and particularly preferably 1 or 2 or 1.

  In the polypeptide (C), “a polypeptide comprising an amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with another amino acid, specifically SEQ ID NOs: 53, 57, 63, 65 , 67, 69, 71, 73, 77, 81, and 85, the sequence identity excluding the amino acid substitution site ”may be 80% or more, preferably 90% or more, more preferably Is 95% or more, particularly preferably 99% or more.

  Here, in the polypeptide of (C), “the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4” means only the arbitrary modified site from the amino acid sequence shown in SEQ ID NO: 4 (that is, This is sequence identity calculated by extracting (except the 46th amino acid) and comparing only the arbitrary modified sites. In addition, “sequence identity” refers to bl2 seq program (TatiaMath, TatiaM., TatiAM. TatiAM., BTI PACKAGE [Sgi32 bit edition, Version 2.0.12; available from National Center for Biotechnology Information (NCBI)]. Microbiol.Lett., Vol.174, p247-250, 1999). The parameters may be set to Matrix: BLOSUM62, Gap insertion Cost value: 11, and Gap extension Cost value: 1.

  Moreover, it is preferable that the amino acid substitution introduce | transduced into the arbitrary modification site | parts of the said polypeptide of (B) and (C) is a conservative substitution. That is, as the substitution at the arbitrary modification site, for example, if the amino acid before substitution is a nonpolar amino acid, substitution to another nonpolar amino acid, and if the amino acid before substitution is an uncharged amino acid, other uncharged amino acids are used. Examples include substitution with an amino acid, substitution with another acidic amino acid if the amino acid before substitution is an acidic amino acid, and substitution with another basic amino acid if the amino acid before substitution is a basic amino acid.

  In the amino acid sequences of the polypeptides (B) and (C), it is preferable that any modification site (for example, active center) involved in the activity is retained without modification.

In the polypeptides (B) and (C), “the affinity for coenzyme NAD is improved as compared with glucose-6-phosphate dehydrogenase having the amino acid sequence shown in SEQ ID NO: 4”. This means that the Km value for NAD obtained in the following [Method for measuring Km value] is lower than the Km value for NAD of wild type G6PDH. The Km is a value represented by the following equation (Michaelis-Menten equation) relating to the reaction rate of the enzyme.

  Here, V is the reaction rate, [S] is the substrate concentration, and Vmax is the reaction rate when the substrate concentration is infinite. Km is generally called the Michaelis-Menten constant and is defined as the substrate concentration at which V is half of Vmax. The above definition is also applied to Km for coenzyme NAD. That is, in the above equation, [S] is calculated as the NAD concentration, and Vmax is calculated as the reaction rate when the NAD concentration is infinite, thereby obtaining Km with respect to NAD. If the Km value for the NAD of the mutant G6PDH is lower than the Km of the wild type G6PDH, a high reaction rate can be obtained for a lower concentration of NAD. In this specification, the case where the Km value for NAD is lower than that of wild-type G6PDH is referred to as “the affinity for coenzyme NAD is improved”.

[Measurement method of Km value]
The following Km measuring reagent is prepared, 0.87 ml of the measuring reagent is put in a spectrophotometer cell, and preincubated for 5 minutes or more at 30 ° C. Add 0.03 mL of enzyme activity measurement solution obtained by diluting G6PDH with the following enzyme diluent to a spectrophotometer cell, mix well, and record absorbance change at 340 nm for 60 seconds with a spectrophotometer pre-incubated at 30 ° C. Then, the change in absorbance per minute (ΔOD / min) is measured. For the blank, the enzyme dilution solution is mixed with the enzyme activity measurement reagent instead of the enzyme activity measurement solution, and the change in absorbance (ΔOD _blank / min) is measured as described above. The reaction rate V is calculated as a value obtained by subtracting ΔOD _blank / min from ΔOD / min, and V at each NAD concentration is recorded.
(Km measuring reagent)
An aqueous solution containing 84 mM Tris-HCl buffer (pH 9.0), 40 mM magnesium chloride, 2.6 mM glucose-6-phosphate, and 0.78 mM to 8.0 mM NAD.
(Enzyme dilution)
50 mM Tris-HCl buffer (pH 8.5)

From the V data at each NAD concentration, Michaelis-Menten constant (Km value) is calculated in the following calculation mode using SigmaPlot software and its Enzyme Kinetics Wizard program (Hulinks).
(Measurement mode)
Number of Substrate: 1
Type of study: Single Substrate
Maximum Number of Velocity Replicates: 2
Analysis: Fit to Model
Equation: Michaelis-Menten
Equation Code: Vmax * S / (Km + S)

  In the present specification, the relative value of the Km value for the NAD of the mutant G6PDH is calculated when the value of the Km value for the NAD of the wild type G6PDH is 100, and the mutant G6PDH having a relative value smaller than 100 is calculated. "Has improved affinity for coenzyme NAD". That is, in the polypeptides (B) and (C), “the affinity for coenzyme NAD is improved as compared with glucose-6-phosphate dehydrogenase having the amino acid sequence shown in SEQ ID NO: 4”. Preferable specific examples of the polypeptide include a polypeptide having a relative value of 99 or less, more preferably 80 or less, more preferably 65 or less, particularly preferably 50 or less, most preferably Preferably, 35 or less polypeptides are mentioned.

In addition, it is desirable that the polypeptides (B) and (C) maintain heat resistance equivalent to or higher than that of wild type G6PDH. Specifically, after being heat-treated at 60 ° C. for 60 minutes after being diluted to a concentration of 1.0 mg / ml in 50 mM Tris-HCl buffer (pH 8.5), the residual rate of G6PDH activity is 50% or more, Preferably it is 90% or more, more preferably 96% or more. Here, the residual rate of G6PDH activity is a value calculated according to the following equation.

Moreover, G6PDH activity is measured on the following measurement conditions using the following reagent.
(reagent)
100 mM Tris-HCl buffer (pH 9.0)
22.5 mM NADP ⁺ aqueous solution 33.0 mM glucose-6-phosphate aqueous solution 1 M magnesium chloride aqueous solution Enzyme activity measuring reagent: Tris-hydrochloric acid buffer solution 25.20 mL, NADP ⁺ aqueous solution 1.20 mL, glucose-6-phosphate 2.40 mL of aqueous solution and 1.20 mL of magnesium chloride aqueous solution are mixed to prepare an enzyme activity measurement reagent.
Enzyme activity measurement solution: 50 mM Tris-HCl buffer (pH 8.5) is used as a solution for diluting the peptide (G6PDH) to a desired concentration (hereinafter also referred to as “enzyme diluent”). The enzyme stock solution (hereinafter also referred to as “enzyme stock solution”) is diluted so that the following activity value is 5 to 10 U / mL to obtain an enzyme activity measurement solution.

(Measurement condition)
Add 3.00 mL of the enzyme activity measurement reagent to the spectrophotometer cell and preincubate at 30 ° C. for 3 minutes or more. Add 0.01 mL of the enzyme activity measurement solution to the spectrophotometer cell, mix well, record the absorbance change at 340 nm for 60 seconds with a spectrophotometer pre-incubated at 30 ° C., and change the absorbance per minute ( [Delta] OD / min) is measured. For the blank, the enzyme dilution solution is mixed with the enzyme activity measurement reagent instead of the enzyme activity measurement solution, and the change in absorbance (ΔOD _blank / min) is measured as described above. From these values, the G6PDH activity per mL is determined according to the following formula.

In the above formula, 3.01 is the amount of the enzyme activity measuring reagent and the enzyme activity measuring solution (mL), 6.22 is the molecular extinction coefficient (cm ² / micromol) of NADP ^{+ under} the present measuring conditions, 01 indicates the amount (mL) of the enzyme activity measurement solution, and 1.0 indicates the optical path length (cm) of the spectrophotometer cell used for enzyme activity measurement.

2. DNA
The DNA encoding the polypeptide of the present invention (hereinafter sometimes referred to as “the DNA of the present invention”) is introduced, for example, so that the amino acid substitution is introduced into the DNA encoding wild type G6PDH. It can be obtained by introducing a mutation.

  Here, the DNA encoding wild type G6PDH is, for example, a microorganism having the base sequence represented by SEQ ID NO: 3, preferably a strain of the genus Geobacillus, more preferably Geobacillus stearothermophilus, particularly preferably Geobacillus. -It can be isolated from the stearothermophilus UK-563 strain by a conventional method using PCR.

  Methods for introducing a specific mutation into a specific site of a base sequence are known, and for example, a site-specific mutagenesis method for DNA can be used. Specific examples of a method for converting a base in DNA include use of a commercially available kit (QuickChange Lightning Site-Directed Mutagenesis kit: manufactured by Stratagene, KOD-Plus-Mutageness kit: manufactured by Toyobo, etc.).

  The base sequence of the DNA thus obtained can be confirmed using a DNA sequencer. For the obtained base sequence, for example, the coding region of the G6PDH gene in the DNA is specified by performing analysis using base sequence analysis software such as DNASIS (manufactured by Hitachi Software Engineering) or GENETIC (software development). be able to.

  Once the base sequence is determined, DNA encoding the polypeptide is obtained by chemical synthesis, PCR using the cloned probe as a template, or hybridization using a DNA fragment having the base sequence as a probe. be able to.

  Furthermore, a mutant form of DNA encoding the peptide having a function equivalent to that before mutation can be synthesized by site-directed mutagenesis or the like. In order to introduce a mutation into the DNA encoding the peptide, a known method such as Kunkel method, Gapped duplex method, megaprimer PCR method or the like can be adopted.

  The base sequence of the DNA of the present invention is not particularly limited as long as it encodes the polypeptide. Specifically, SEQ ID NOs: 52, 56, 62, 64, 66, 68, 70, 72, Examples include the base sequences shown in 76, 80 and 84.

  SEQ ID NO: 52 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 53. SEQ ID NO: 56 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 57. SEQ ID NO: 62 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 63. SEQ ID NO: 64 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 65. SEQ ID NO: 66 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 67. SEQ ID NO: 68 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 69. SEQ ID NO: 70 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 71. SEQ ID NO: 72 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 73. SEQ ID NO: 76 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 77. SEQ ID NO: 80 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 81. SEQ ID NO: 84 is the base sequence of DNA encoding the polypeptide consisting of the amino acid sequence shown in SEQ ID NO: 85.

  Among the DNAs of the present invention, the DNA consisting of the base sequences shown in SEQ ID NOs: 64, 76 and 80, particularly the DNA consisting of the base sequence shown in SEQ ID NO: 76, has a markedly improved affinity for coenzyme NAD. And is a suitable DNA.

  The DNA of the present invention encodes a polypeptide having G6PDH activity and having improved affinity for coenzyme NAD compared to G6PDH (wild type G6PDH) consisting of the amino acid sequence shown in SEQ ID NO: 4. And a DNA comprising a base sequence complementary to the DNA comprising the base sequence shown in SEQ ID NO: 52, 56, 62, 64, 66, 68, 70, 72, 76, 80 or 84, under stringent conditions Hybridizing DNA is included.

  Here, “stringent conditions” means 0.5% SDS, 5 × Denhartz [Denhartz's, 0.1% bovine serum albumin (BSA), 0.1% polyvinylpyrrolidone, 0.1% Ficoll. 400] and 100 μg / ml salmon sperm DNA (1 × SSC is 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0) at 50 ° C. to 65 ° C. for 4 hours to overnight. This refers to the conditions for keeping warm.

  Specifically, hybridization under stringent conditions is performed by the following method. That is, a nylon membrane on which a DNA library or cDNA library is immobilized is prepared, and a prehybridization solution containing 6 × SSC, 0.5% SDS, 5 × Denharz, 100 μg / ml salmon sperm DNA at 65 ° C. Block nylon membrane. Thereafter, each probe labeled with 32P is added and incubated overnight at 65 ° C. This nylon membrane was placed in 6 × SSC for 10 minutes at room temperature, in 2 × SSC containing 0.1% SDS, for 10 minutes at room temperature, in 0.2 × SSC containing 0.1% SDS for 30 minutes at 45 ° C. After washing, autoradiography can be taken to detect DNA specifically hybridized with the probe.

  Furthermore, the DNA of the present invention encodes a polypeptide having G6PDH activity and having improved affinity for coenzyme NAD as compared to G6PDH (wild type G6PDH) consisting of the amino acid sequence shown in SEQ ID NO: 4, Also included are DNAs having a homology of 80% or more to the DNA comprising the nucleotide sequence shown in SEQ ID NOs: 52, 56, 62, 64, 66, 68, 70, 72, 76, 80 or 84. The homology is preferably 90% or more, more preferably 95% or more, and particularly preferably 98% or more.

  Here, “homology” of DNA refers to blst pacage. Blast PACKAGE [sgi32 bit edition, Version 2.0.12; available from the National Center for Biotechnology Information (NCBI). (Madden, FEMS Microbiol. Lett., Vol. 174, 247-250, 1999). Parameters are set with default settings.

  The DNA of the present invention can also be artificially synthesized by a total gene synthesis method. In that case, DNA designed to optimize the codon usage frequency in the base sequence of the DNA to the codon usage frequency of the host to be used can be artificially synthesized.

What is necessary is just to employ | adopt the total of the host optimal codon usage frequency of each codon as a parameter | index showing codon usage frequency. The optimal codon is defined as the codon that is most frequently used among codons corresponding to the same amino acid. The codon usage frequency is not particularly limited as long as it is optimized for the host. Examples of the codon usage frequency of E. coli include the following.
F: phenylalanine (ttt), L: leucine (ctg), I: isoleucine (att), M: methionine (atg), V: valine (gtg), Y: tyrosine (tat), stop codon (taa), H: Histidine (cat), Q: glutamine (cag), N: asparagine (aat), K: lysine (aaa), D: aspartic acid (gat), E: glutamic acid (gaa), S: serine (agc), P: Proline (ccg), T: threonine (acc), A: alanine (gcg), C: cysteine (tgc), W: tryptophan (tgg), R: arginine (cgg), G: glycine (ggc).

3. Recombinant vector A recombinant vector containing DNA encoding the polypeptide of the present invention (hereinafter sometimes referred to as the recombinant vector of the present invention) can be obtained by inserting the DNA of the present invention into an expression vector. it can.

  The recombinant vector of the present invention includes regulatory elements such as a promoter operably linked to the DNA of the present invention. A typical example of a control factor is a promoter, but a transcription element such as an enhancer, a CCAAT box, a TATA box, or an SPI site may be further included as necessary. The term “operably linked” means that various regulatory factors such as promoters and enhancers that regulate the DNA of the present invention and the DNA of the present invention are linked in a state in which they can operate in a host cell.

  Suitable expression vectors are those constructed for genetic recombination from phages or plasmids that can grow autonomously in the host.

  Examples of the phage include Lambda gt10 and Lambda gt11 when Escherichia coli described later is used as a host.

  Examples of the plasmid include pBR322, pUC18, pUC118, pUC19, pUC119, pTrc99A, pBluescript, and Super Cos I which is a cosmid when Escherichia coli is used as a host.

  When Pseudomonas is used as the host, RSF1010, pBBR122, pCN51, etc., which are broad host range vectors for Gram-negative bacteria, can be mentioned. Furthermore, animal viruses such as retrovirus and vaccinia virus, and insect virus vectors such as baculovirus can also be used.

4). Transformant A transformant (hereinafter sometimes referred to as “transformant of the present invention”) is obtained by transforming a host using the recombinant vector of the present invention.

  The host used for the production of the transformant is not particularly limited as long as the recombinant vector is stable, can autonomously proliferate, and can express a foreign gene trait. For example, Escherichia coli, etc. Bacteria belonging to the genus Escherichia, Bacillus subtilis such as Bacillus subtilis, Pseudomonas putida such as Pseudomonas putida; yeast; animal cells such as COS cells; insect cells such as Sf9; Plant bodies (eg leaves, petals, stems, roots, seeds, etc.), plant tissues (eg epidermis, phloem, parenchyma, xylem, vascular bundles, etc.), plant culture cells, etc. It is done. Among these, E. coli is preferable, and E. coli DH5α, E. coli BL21, and E. coli XL-1 Blue MR are more preferable.

  The transformant of the present invention can be obtained by introducing the recombinant vector of the present invention into a host, and the conditions for introducing the recombinant vector into the host may be appropriately set according to the type of the host. When the host is a bacterium, for example, a method using competent cells by calcium ion treatment, an electroporation method and the like can be mentioned. When the host is yeast, for example, electroporation method (electroporation method), spheroplast method, lithium acetate method and the like can be mentioned. When the host is an animal cell, examples thereof include an electroporation method, a calcium phosphate method, and a lipofection method. When the host is an insect cell, examples include calcium phosphate method, lipofection method, electroporation method and the like. When the host is a plant vesicle, examples thereof include an electroporation method, an Agrobacterium method, a particle gun method, and a PEG method.

  Whether or not the recombinant vector of the present invention has been incorporated into the host can be confirmed by PCR, Southern hybridization, Northern hybridization, or the like.

  When confirming whether or not the recombinant vector of the present invention has been incorporated into the host by PCR, for example, the recombinant vector may be separated and purified from the transformant.

  For example, when the host is a bacterium, the recombinant vector is separated and purified based on a lysate obtained by lysing the bacterium. As a method for lysis, for example, treatment is performed with a lytic enzyme such as lysozyme, and a protease and other enzymes and a surfactant such as sodium lauryl sulfate (SDS) are used in combination as necessary.

  Furthermore, physical crushing methods such as freeze thawing and French press treatment may be combined. Separation and purification of DNA from the lysate can be performed by, for example, appropriately combining a deproteinization treatment by a phenol treatment and a protease treatment, a ribonuclease treatment, an alcohol precipitation treatment, and a commercially available kit.

  The DNA can be cleaved according to a conventional method, for example, using a restriction enzyme treatment. As a restriction enzyme, for example, a type II restriction enzyme that acts on a specific nucleotide sequence is used. The DNA and the expression vector are bound using, for example, DNA ligase.

  Thereafter, PCR is performed by designing primers specific to the DNA of the present invention using the separated and purified DNA as a template. The amplification product obtained by PCR is subjected to agarose gel electrophoresis, polyacrylamide gel electrophoresis, capillary electrophoresis, etc., stained with ethidium bromide and SYBR Green solution, etc., and the amplification product is detected as a band to You can confirm that it has been converted.

  Moreover, PCR can be performed using a primer previously labeled with a fluorescent dye or the like to detect an amplification product. Furthermore, a method of binding an amplification product to a solid phase such as a microplate and confirming the amplification product by fluorescence, enzyme reaction, or the like may be employed.

4). Production of Polypeptide The polypeptide of the present invention can be produced by culturing the transformant of the present invention.

  The culture form of the transformant of the present invention may be selected in consideration of the nutritional physiological properties of the host, and preferably liquid culture. Industrially, aeration and agitation culture is advantageous.

  As a nutrient source of the medium, those required for the growth of the transformant can be used. The carbon source may be any carbon compound that can be assimilated, and examples thereof include glucose, sucrose, lactose, maltose, molasses, and pyruvic acid.

  The nitrogen source may be any assimilable nitrogen compound, and examples thereof include peptone, meat extract, yeast extract, casein hydrolyzate, and soybean meal alkaline extract.

  In addition to the carbon source and nitrogen source, for example, salts such as phosphate, carbonate, sulfate, magnesium, calcium, potassium, iron, manganese and zinc, specific amino acids and specific vitamins are used as necessary May be.

  The culture temperature can be appropriately set within the range in which the transformant of the present invention can grow and the transformant of the present invention produces the polypeptide of the present invention, and is preferably about 15 to 37 ° C. . The culture may be completed at an appropriate time in anticipation of the time when the polypeptide of the present invention reaches the maximum yield. Usually, the culture time is about 12 to 48 hours.

  The pH of the medium can be appropriately changed within the range where the host grows and the host produces mutant G6PDH, but is preferably in the range of about pH 5.0 to 9.0.

  The transformant of the present invention is cultured, and the culture supernatant or cells are collected by a method such as centrifugation, and the cells are treated with a mechanical method such as ultrasonic and French press or a lytic enzyme such as lysozyme. It is solubilized by using an enzyme such as protease or a surfactant such as sodium lauryl sulfate (SDS) as necessary, and a water-soluble fraction containing the polypeptide of the present invention can be obtained.

  Moreover, the expressed polypeptide of the present invention can be secreted into the culture medium by selecting an appropriate expression vector and host.

  The water-soluble fraction containing the polypeptide of the present invention obtained as described above may be subjected to purification treatment as it is. However, after the polypeptide of the present invention in the water-soluble fraction is concentrated, the water-soluble fraction is subjected to purification treatment. May be provided.

  Concentration can be performed by, for example, vacuum concentration, membrane concentration, salting out treatment, fractional precipitation with a hydrophilic organic solvent (for example, methanol, ethanol and acetone).

  The polypeptide of the present invention can be purified by, for example, appropriately combining methods such as gel filtration, adsorption chromatography, ion exchange chromatography, affinity chromatography and the like.

  The said refinement | purification process is already well-known and can be advanced by referring an appropriate literature, a magazine, a textbook, etc. The polypeptide of the present invention thus purified can be pulverized by lyophilization, vacuum drying, spray drying or the like and distributed to the market as necessary.

  EXAMPLES Next, the present invention will be specifically described with reference to examples, but the present invention is not limited to the following examples. In the following Reference Examples and Examples, unless otherwise stated, measurement of G6PDH activity, measurement of Km value for NAD, and the like were performed under the conditions described above.

Reference Example 1: Acquisition of wild type G6PDH gene and acquisition of recombinant vector for expression (1-1) Isolation and sequencing of wild type G6PDH gene Water suspension of Geobacillus stearothermophilus UK-563 strain, Oligonucleotides (operated by Operon Biotechnology Co., Ltd.) having the base sequences shown in SEQ ID NO: 1 and SEQ ID NO: 2 were prepared. PCR reaction solutions shown in Table 1 were prepared, and PCR was carried out for 30 cycles of 98 ° C .: 10 seconds, 54 ° C .: 30 seconds, 68 ° C .: 90 seconds.

  As a result of agarose gel electrophoresis, it was confirmed that a DNA fragment of about 1.5 kbp was amplified. In accordance with 0.5 μl of the PCR reaction solution, the reagent attached to Zero Blunt (registered trademark) TOPO (registered trademark) PCR Cloning kit (manufactured by Invitrogen), and the method described in the instruction manual, the reaction solutions shown in Table 2 were prepared. .

  The reaction solution was incubated at room temperature for 5 minutes, and an approximately 1.5 kbp DNA fragment amplified by the PCR reaction was ligated to the cloning vector pCRII-Blunt-TOPO (registered trademark). 1 μl of the reaction solution is added to 10 μl of E. coli TOP10 chemical competent cell, transformed by heat shock at 42 ° C., and LB agar medium (1.0% tryptone, 0.5% yeast extract, 1.0% chloride) Sodium, 1.5% agar, 0.1 g / ml ampicillin) was cultured at 37 ° C. for 18 hours, and transformant colonies appeared. A single colony was inoculated in an LB liquid medium and cultured overnight, and then the plasmid was purified by the alkali-SDS method. DNA sequencing was performed using the plasmid DNA, M13 Forward (−20) Primer, and M13 Reverse Primer, and the nucleotide sequence of the above 1.5 kbp DNA was decoded. As a result, the nucleotide sequence of SEQ ID NO: 3 was found. The polypeptide encoded by the DNA was confirmed to have the amino acid sequence shown in SEQ ID NO: 4.

  When the amino acid sequence shown in SEQ ID NO: 4 was queried in the database of National Center for Biotechnology Information (NCBI), there was no completely identical sequence data, but 10 already identified Geobacillus stearothermophilus strains Since the amino acid sequence of the derived G6PDH and all except 6 amino acid residues are identical and the homology is extremely high, it was estimated to be a novel G6PDH.

  Hereinafter, the plasmid used for decoding the base sequence is also referred to as pTOPOG6PDH.

(1-2) Expression vector pTrc99A (manufactured by Pharmacia Biotech) was selected as the expression vector. pTrc99A contains a trc promoter sequence upstream of the multiple cloning site (MCS) and a transcription termination signal sequence downstream of MCS. The MCS contains a restriction enzyme NcoI recognition sequence and a restriction enzyme BamHI recognition sequence. Since the NcoI recognition sequence is juxtaposed to the trc promoter sequence, the DNA fragment having the ATG of the translation initiation codon is directly bound to the MCS. Can be expressed. The size of pTrc99A is about 4.2 kbp.

(1-3) Pretreatment of expression vector Pretreatment of pTrc99A to obtain a recombinant vector for expression was performed by the following procedure. Reaction solutions shown in Table 3 were prepared, and incubated at 37 ° C. for 3 hours, whereby about 2 μg of pTrc99A was cleaved with restriction enzyme NcoI (manufactured by Takara Bio Inc.).

  The reaction solution was subjected to agarose gel electrophoresis to cut out a DNA fragment of about 4.2 kbp. The DNA fragment was purified using Wizard (registered trademark) SV Gel and PCR Clean-Up System (manufactured by Promega Corporation). The ends of the purified DNA fragment were blunted using Blunting high (manufactured by Toyobo Co., Ltd.), and the DNA fragment was purified. By preparing the reaction solutions shown in Table 4 and incubating at 30 ° C. for 3 hours, about 1 μg of the smoothed DNA fragment was cleaved with the restriction enzyme BamHI (Takara Bio Inc.).

  The reaction solution was purified by the above-described electrophoresis and gel extraction procedures, and used for the synthesis of the following recombinant vector for expression.

(1-4) Pretreatment of G6PDH gene Pretreatment for obtaining a recombinant vector for expression was performed by the following procedure. The oligonucleotide DNAs described in SEQ ID NO: 5 and SEQ ID NO: 6 were prepared. The PCR reaction solution shown in Table 5 was prepared, and PCR was carried out for 18 cycles of 98 ° C .: 10 seconds, 52 ° C .: 30 seconds, 68 ° C .: 90 seconds.

  A part of the PCR reaction solution was subjected to agarose gel electrophoresis to confirm that an about 1.5 kb DNA fragment was amplified, and the PCR reaction solution was subjected to ethanol precipitation to purify the DNA fragment. The purified DNA fragment was treated with the restriction enzyme BamHI in the same manner as the vector, purified by the above-described agarose gel electrophoresis and gel extraction procedures, and used for the synthesis of the following recombinant vector for expression.

(1-5) Synthesis of Recombinant Vector for Expression The DNA fragment of pTrc99A pretreated as described above and the DNA fragment of G6PDH were bound by the action of T4 ligase using Ligation high (manufactured by Toyobo Co., Ltd.). 1 μl of the reaction solution is added to 10 μl of E. coli DH5α chemical competent cell (manufactured by Takara Bio Inc.), transformed by heat shock at 42 ° C., and cultured on LB agar medium at 37 ° C. for 18 hours. Transformant colonies appeared. A colony of a transformant containing a G6PDH fragment was selected by colony PCR using a PCR reaction solution mixed with a template DNA other than the template DNA shown in Table 5, and the colony was inoculated in an LB liquid medium and cultured overnight. -Plasmid was purified by SDS method.

  As a result of DNA sequencing using the plasmid DNA, the oligonucleotides shown in SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 as a material, a DNA fragment consisting of the sequence shown in SEQ ID NO: 3 was converted into an NcoI recognition sequence and a BamHI recognition sequence of pTrc99A. It was confirmed that they were joined in between. Hereinafter, the plasmid is also referred to as pTrcG6PDH.

Reference Example 2: Recombinant expression of wild type G6PDH, evaluation of heat resistance, and purification (2-1) Production and culture of transformant Colony of transformant obtained by transforming E. coli BL21 (manufactured by Takara Bio Inc.) with pTrcG6PDH Prepared. For comparison, a colony of a transformant obtained by transforming E. coli BL21 with pTrc99A was also prepared.

  Each colony was inoculated into 2 mL of LB medium containing 100 μg / mL ampicillin and cultured with shaking at 37 ° C. for 16 hours. The obtained LB culture solution was autoclaved in advance and 100 μg / mL ampicillin and 0.2 mM. Of isopropyl-β-thiogalactopyranoside (manufactured by Wako Pure Chemical Industries, Ltd.) in 100 mL of Terrific culture solution (1.2% tryptone, 2.4% yeast extract, 0.4% glycerol, 0.23%) Inoculated into potassium dihydrogen phosphate and 1.25% dipotassium hydrogen phosphate. Each of the culture solutions was cultured at 37 ° C. for 22 hours.

(2-2) Activity measurement and heat resistance evaluation Transformants after culture were collected by centrifugation at 6,000 × g for 10 minutes, and 40 ml of 20 mM Tris buffer (pH 9.0) was added to the cells. Was suspended and crushed by ultrasonic crushing. The crushed liquid was centrifuged at 10,000 × g for 20 minutes, and the supernatant was collected. The supernatant was used as a crude enzyme solution for activity measurement.

  At the same time, the crude enzyme solution was heat treated at 60 ° C. for 60 minutes, and the activity of the sample after the heat treatment was also measured. As a comparative example, the enzyme activity before and after heat treatment of Leuconostoc mesenteroides-derived G6PDH (manufactured by SIGMA) was also measured. The results of activity measurement and heat resistance evaluation are shown in Table 6.

  The enzyme activity of the crude enzyme solution prepared from the transformant transformed with pTrc99A was 0.1 U / mL. On the other hand, the enzyme activity of the crude enzyme solution prepared from the transformant transformed with pTrcG6PDH was 28.9 U / mL, confirming the G6PDH activity specific to the G6PDH gene derived from Geobacillus stearothermophilus. The enzyme activity of the G6PDH crude enzyme solution derived from Geobacillus stearothermophilus after heat treatment was 28.0 U / mL, and the activity was maintained at 96.9%. On the other hand, the Leuconostoc mesenteroides-derived G6PDH used as a comparative example was completely inactivated.

  From the above results, G6PDH (SEQ ID NO: 4) derived from Geobacillus stearothermophilus can be produced by culturing a transformant of any combination of vector and host, and G6PDH produced by the above production method is It was revealed that the heat-resistant G6PDH has an activity of 95% or more even after heat treatment at 60 ° C. for 60 minutes. This property is advantageous for shortening the purification process because the host protein can be denatured and removed by heat treatment while maintaining G6PDH activity in enzyme purification from the transformant.

(2-3) Purification G6PDH was purified using the crude enzyme solution. The crude enzyme solution was heat-treated at 60 ° C. for 60 minutes and then rapidly cooled. The host-derived contaminants containing the denatured protein were precipitated by centrifugation at 10,000 × g for 40 minutes, and the supernatant was collected. It was adsorbed on a RESOURCE Q column (manufactured by GE Healthcare) equilibrated with 20 mM Tris-HCl buffer (pH 9.0). The G6PDH active fraction was eluted by a concentration gradient from 0M to 1M sodium chloride. Ammonium sulfate was added to the G6PDH active fraction so as to be 40% saturated, and adsorbed on a RESOURCE PHE column (manufactured by GE Healthcare) equilibrated with 20 mM Tris-HCl buffer (pH 9.0) containing 40% saturated ammonium sulfate. I let you. The G6PDH active fraction was eluted by a concentration gradient from 40% to 0% saturated ammonium sulfate. The fractions were collected, concentrated by Amicon (registered trademark) Ultra-15 (Millipore), and buffer exchanged to 20 mM Tris-HCl buffer (pH 8.5). The obtained G6PDH active fraction was subjected to SDS-PAGE, and only a single band of about 55 kDa was observed, so it was designated as purified G6PDH. Hereinafter, this enzyme may be simply referred to as wild type G6PDH.

Example 1: Site-directed mutagenesis, recombinant expression and purification of mutant G6PDH into wild type G6PDH gene (3-1) Site-directed mutagenesis Amino acid sequence of wild type G6PDH (amino acid sequence shown in SEQ ID NO: 4) The site-directed mutagenesis by PCR was carried out using the oligonucleotides shown in Table 7 designed to change the 46th arginine (R) in () to another amino acid residue. The oligonucleotide was designed to replace the arginine codon (CGC) between positions 124 and 150 of the nucleotide sequence shown in SEQ ID NO: 3, and its complementary strand was also designed. For example, the R46F mutant was prepared by using the oligonucleotide shown in SEQ ID NO: 10 in which the codon (CGC) was replaced with the codon of phenylalanine (TTC) and the oligonucleotide shown in SEQ ID NO: 11 of its complementary strand. The above-mentioned pTrcG6PDH was used as a PCR template, and a commercially available Quik Change Lightning Site-Directed Mutagenesis Kit (manufactured by Agilent Technologies) was used. The method was in accordance with the instruction manual attached to the kit.

  1 μl of each of the 19 kinds of site-directed mutagenesis reaction solutions was added to 10 μl each of E. coli DH5α chemical competent cells, transformed by heat shock at 42 ° C., and cultured on LB agar medium at 37 ° C. for 18 hours. Transformant colonies appeared. The colony was inoculated in LB liquid medium and cultured overnight, and then the plasmid was purified by the alkali-SDS method. As a result of DNA sequencing using the oligonucleotides shown in the plasmid DNA, SEQ ID NO: 7, SEQ ID NO: 8 and SEQ ID NO: 9 as a material, 19 types of mutations were introduced, and nucleotide sequences containing no unexpected mutation by PCR I confirmed that there was. That is, the mutant R46F gene had the base sequence shown in SEQ ID NO: 48, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 49. The mutant R46L gene had the base sequence shown in SEQ ID NO: 50, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 51. The mutant R46I gene had the base sequence shown in SEQ ID NO: 52, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 53. The mutant R46M gene had the base sequence shown in SEQ ID NO: 54, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 55. The mutant R46V gene had the base sequence shown in SEQ ID NO: 56, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 57. The mutant R46Y gene had the base sequence shown in SEQ ID NO: 58, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 59. The mutant R46H gene had the base sequence shown in SEQ ID NO: 60, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 61. The mutant R46Q gene had the base sequence shown in SEQ ID NO: 62, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 63. The mutant R46N gene has the base sequence shown in SEQ ID NO: 64, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 65. The mutant R46K gene has the base sequence shown in SEQ ID NO: 66, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 67. The mutant R46D gene had the base sequence shown in SEQ ID NO: 68, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 69. The mutant R46E gene has the base sequence shown in SEQ ID NO: 70, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 71. The mutant R46S gene has the base sequence shown in SEQ ID NO: 72, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 73. The mutant R46P gene had the base sequence shown in SEQ ID NO: 74, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 75. The mutant R46T gene had the base sequence shown in SEQ ID NO: 76, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 77. The mutant R46A gene had the base sequence shown in SEQ ID NO: 78, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 79. The mutant R46C gene has the base sequence shown in SEQ ID NO: 80, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 81. The mutant R46W gene has the base sequence shown in SEQ ID NO: 82, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 83. The mutant R46G gene had the base sequence shown in SEQ ID NO: 84, and the base sequence encoded the amino acid sequence shown in SEQ ID NO: 85.

(3-2) Recombinant Expression and Purification of Mutant G6PDH By obtaining and culturing a transformant according to the method described in Reference Example 2, using each of the above-described 19 recombinant vectors containing mutant genes. Mutant G6PDH was expressed. A part of the culture solution is collected and the transformant is collected by centrifugation, suspended in 1 ml of 20 mM Tris buffer (pH 9.0), sonicated, and the centrifuged supernatant is used as a crude enzyme solution to measure the activity. It was used for. Since any mutant detected G6PDH activity, it was purified according to the method described in Reference Example 2.

Example 2: Comparison of affinity and heat resistance of mutant G6PDH to coenzyme NAD (4-1) Comparison of affinity to coenzyme NAD Wild type G6PDH purified in Reference Example 2 and Example 1 Using the 19 types of mutant G6PDH purified in step 1, “Km value for NAD”, which is an index of affinity for coenzyme NAD, was determined.

The reagent for measuring the Km value was adjusted to 84 mM Tris-HCl buffer (pH 9.0), 40 mM magnesium chloride, 2.6 mM glucose-6-phosphate, and 0.78 mM to 8.0 mM NAD, respectively. Using each purified enzyme diluted with 50 mM Tris-HCl buffer (pH 8.5), the enzyme activity was measured with a reagent for measuring Km value adjusted to each NAD concentration. A Michaelis-Menten plot in which the vertical axis represents enzyme activity and the horizontal axis represents NAD concentration was prepared, and the NAD concentration when the Vmax on the vertical axis was halved was used as the Km value for NAD, using SigmaPlot (manufactured by Hulinks). The Km value for NAD was determined. Table 8 shows the relative values (Km ^NAD relative values) of the mutants when the Km value for NAD of wild-type G6PDH is 100%.

  From Table 8, the Km values of Mutant R46I, Mutant R46V, Mutant R46Q, Mutant R46N, Mutant R46K, Mutant R46D, Mutant R46E, Mutant R46S, Mutant R46T, Mutant R46C, and R46G are It was found that the affinity with respect to the coenzyme NAD was improved with respect to the wild type G6PDH. In particular, the effects of R46N, R46T, and R46C were significant.

(4-2) Comparison of heat resistance The wild type G6PDH and 19 types of mutant G6PDH were diluted with 50 mM Tris-HCl buffer (pH 8.5) to a protein concentration of 1.0 mg / ml. The diluted enzyme solution was heat-treated at 60 ° C. for 60 minutes. Table 9 shows the residual ratio (%) of G6PDH activity after the heat treatment. As a comparative example, the measurement result of Leuconostoc mesenteroides-derived G6PDH (manufactured by SIGMA) is also shown.

  As shown in Table 9, the residual rate of purified wild-type G6PDH was 96%, and the residual rate of 19 mutant G6PDHs was almost the same as that of wild-type G6PDH. Thus, it was shown that mutating the 46th arginine does not affect the heat resistance. Moreover, since G6PDH derived from Leuconostoc mesenteroides used in the comparative example was completely inactivated by the same heat treatment, it was shown that the wild type G6PDH and the mutant G6PDH of the present invention have relatively high heat resistance. It was done.

  INDUSTRIAL APPLICABILITY According to the present invention, a mutant G6PDH that can be used in a wide range of applications including industrial applications and has high heat resistance and high affinity for coenzyme NAD can be provided by genetic engineering techniques. Furthermore, the present invention also provides a gene required for mass production of mutant G6PDH, a recombinant vector containing the gene, a transformant obtained from the vector, and a method for producing mutant G6PDH using the transformant. .

Claims (10)

The polypeptide shown in any of the following (A) to (C):
(A) The 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is any one selected from the group consisting of threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine A polypeptide comprising an amino acid sequence substituted with an amino acid,
(B) The 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is any one selected from the group consisting of threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine In the amino acid sequence substituted with an amino acid, one or several amino acids other than the 46th amino acid are substituted, added, inserted or deleted, and have glucose-6-phosphate dehydrogenase activity, A polypeptide having an improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in No. 4;
(C) The 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is any one selected from the group consisting of threonine, cysteine, asparagine, glutamic acid, aspartic acid, serine, glutamine, lysine, valine, isoleucine, and glycine In the amino acid sequence substituted with an amino acid, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, and has glucose-6-phosphate dehydrogenase activity, A polypeptide having an improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase comprising the amino acid sequence shown in SEQ ID NO: 4. The polypeptide shown in any of the following (A) to (C):
(A) a polypeptide comprising an amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with threonine;
(B) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with threonine, one or several amino acids other than the 46th amino acid are substituted, added, inserted or deleted, and Polypeptide having glucose-6-phosphate dehydrogenase activity and improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 ,
(C) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with threonine, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, In addition, poly having a glucose-6-phosphate dehydrogenase activity and an improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase having the amino acid sequence shown in SEQ ID NO: 4 peptide. The polypeptide shown in any of the following (A) to (C):
(A) a polypeptide comprising an amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with cysteine,
(B) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with cysteine, one or several amino acids other than the 46th amino acid are substituted, added, inserted or deleted, and Polypeptide having glucose-6-phosphate dehydrogenase activity and improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 ,
(C) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with cysteine, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, In addition, poly having a glucose-6-phosphate dehydrogenase activity and an improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase having the amino acid sequence shown in SEQ ID NO: 4 peptide. The polypeptide shown in any of the following (A) to (C):
(A) a polypeptide comprising an amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with asparagine;
(B) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with asparagine, one or several amino acids other than the 46th amino acid are substituted, added, inserted or deleted, and Polypeptide having glucose-6-phosphate dehydrogenase activity and improved affinity for coenzyme NAD as compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 ,
(C) In the amino acid sequence in which the 46th amino acid in the amino acid sequence shown in SEQ ID NO: 4 is substituted with asparagine, the sequence identity excluding the 46th amino acid with respect to the amino acid sequence shown in SEQ ID NO: 4 is 80% or more, In addition, poly having a glucose-6-phosphate dehydrogenase activity and an improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase having the amino acid sequence shown in SEQ ID NO: 4 peptide.   DNA encoding the polypeptide according to any one of claims 1 to 4. The DNA according to claim 5, which is the DNA shown in (i) or (ii) below.
(I) SEQ ID NO: 76, 80, 64, 52, 56, 62, 66, 68, 70, 72, or 8
DNA comprising the base sequence shown in 4,
(Ii) Glucose-6-phosphate dehydrogenase activity and improved affinity for coenzyme NAD compared to glucose-6-phosphate dehydrogenase consisting of the amino acid sequence shown in SEQ ID NO: 4 DNA encoding a polypeptide and comprising a base sequence complementary to DNA consisting of the base sequence shown in SEQ ID NOs: 76, 80, 64, 52, 56, 62, 66, 68, 70, 72, or 84; DNA that hybridizes under stringent conditions.   A recombinant vector comprising the DNA according to claim 5 or 6.   A transformant obtained by transforming a host with the recombinant vector according to claim 7.   The transformant according to claim 8, wherein the host is Escherichia coli.   The manufacturing method of the polypeptide in any one of Claims 1-4 including the process of culture | cultivating the transformant of Claim 8 or 9.